This month’s issue of Life Science Compliance Update focuses on the importance of compliance culture. First, we examine the difference between what current CIA’s require in compliance programs versus what the Ethics and Compliance Initiative’s Blue Ribbon Panel suggests. Tracey Keele from KPMG then explores whether improving culture will address the pharmaceutical industry’s image problem. Other highlights this month include an article by Huron’s Chris Cobourn on the recently finalized rule on Average Medicaid Price (“AMP”) calculations and Kaitlin Fallon does a comparison review of some of the global codes of practices and ethics governing life sciences commercial operation.
March Issue of Life Science Compliance Update Is Here!
Mar 3, 2016